1
|
Vriesendorp HM, Quadri SM, Stinson RL, Onyekwere OC, Shao Y, Klein JL, Leichner PK, Williams JR. Selection of reagents for human radioimmunotherapy. Int J Radiat Oncol Biol Phys 1992; 22:37-45. [PMID: 1727128 DOI: 10.1016/0360-3016(92)90980-v] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Promising response rates are noted in patients with refractory Hodgkin's disease after radioimmunoglobulin therapy (RIT) with Yttrium-90 labeled polyclonal antiferritin. To explore the most efficacious selection of RIT reagents for use in humans, experimental animal data are reviewed for radiolabeled antiferritin and B72.3. Nude mice with subcutaneously implanted human malignancies provide an excellent primary screen for radiolabeled antibodies under consideration for use in humans. They provide information on the potential of a new reagent to target a human malignancy in vivo. The other determinant of the therapeutic ratio of RIT reagents--normal tissue toxicity--is best analyzed in large animals, such as dogs. Hematologic toxicity is dose limiting in all species and best predicted by a prescription of radiolabeled antibodies in mCi per kilogram body weight and the presence or absence of bone marrow targeting. Per cGy, RIT is more effective in causing BM damage in dogs than in rats. In dogs, bone marrow transplantation with autologous cryopreserved bone marrow cells or G-CSF treatment can accelerate hemopoietic recovery and granulopoiesis, respectively, after RIT. When dose escalation beyond bone marrow toxicity is performed, the liver (dog) or the intestinal tract (rat) become the next dose limiting tissue in dose escalation studies. Significant improvement in RIT results will be achieved when the normal liver uptake of chelated monoclonal antibody in dogs and in human patients can be prevented. The described animal models and continued investigations of RIT in patients with endstage Hodgkin's disease will allow for further improvement in the therapeutic ratio of RIT and the applicability of RIT in humans.
Collapse
Affiliation(s)
- H M Vriesendorp
- Johns Hopkins Oncology Center, Section of Radiobiology, Baltimore, MD 21205
| | | | | | | | | | | | | | | |
Collapse
|
2
|
Saiful Alam AF. Radioimmunotherapy of human hepatocellular carcinoma xenografts with 131I-labelled antiferritin antibody. Br J Cancer 1991; 63:503-7. [PMID: 2021533 PMCID: PMC1972350 DOI: 10.1038/bjc.1991.120] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
The effects of 131-labelled antiferritin polyclonal antibody for the treatment of established hepatocellular carcinoma (HC-04) in athymic nude mice were evaluated. 131I-labelled antiferritin antibody localised specifically to a subcutaneous tumour with a mean of 8.1% of the infused dose per gram of tumour at 24 h after infusion when the experiment was started 15 days after inoculation and with a mean of about 6.5% of the infused dose per gram of tumour when the experiment was started 30 days after tumour transplantation. The concentrations of 131I-antiferritin antibody in tumour delivered a mean of 1994 cGy to tumour following infusion of 500 microCi of radiolabelled antiferritin antibody in the early group and a mean of 1600 cGy in the late group. Treatment with 500 microCi led to regression of the tumour in 55% of animals in the early group and 44% in the late group. In contrast, unlabelled antiferritin and 131I-labelled IgG failed to exert any significant effect on tumour growth. The transplanted tumours in the early groups of animals had relatively higher concentration of ferritin than those in the late group. There was accelerated inhibition of tumour growth and prolonged survival in animals in the early group compared with those in the late group.
Collapse
Affiliation(s)
- A F Saiful Alam
- First Department of Surgery, Hokkaido University School of Medicine, Sapporo, Japan
| |
Collapse
|
3
|
Williams JA, Wessels BW, Wharam MD, Order SE, Wanek PM, Poggenburg JK, Klein JL. Targeting of human glioma xenografts in vivo utilizing radiolabeled antibodies. Int J Radiat Oncol Biol Phys 1990; 18:1367-75. [PMID: 2370186 DOI: 10.1016/0360-3016(90)90310-g] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Radiolabeled antibodies provide a potential basis for selective radiotherapy of human gliomas. We have measured tumor targeting by radiolabeled monoclonal and polyclonal antibodies directed against neuroectodermal and tumor-associated antigens in nude mice bearing human glioma xenografts. Monoclonal P96.5, a mouse IgG2a immunoglobulin, defines an epitope of a human melanoma cell surface protein, and specifically binds the U-251 human glioma as measured by immunoperoxidase histochemistry. 111In-radiolabeled P96.5 specifically targets the U-251 human glioma xenograft and yields 87.0 microCuries (microCi) of tumor activity per gram per 100 microCi injected activity compared to 4.5 microCi following administration of radiolabeled irrelevant monoclonal antibody. Calculations of targeting ratios demonstrate deposited dose to be 11.6 times greater with radiolabeled P96.5 administration compared to irrelevant monoclonal antibody. The proportion of tumor dose found in normal organs is less than 10%, further supporting specific targeting of the human glioma xenograft by this antibody. Monoclonal antibody ZME018, which defines a second melanoma-associated antigen, and polyclonal rabbit antiferritin, which defines a tumor-associated antigen, demonstrate positive immunoperoxidase staining of the tumor, but comparatively decreased targeting. When compared to the 111In-radiolabeled antibody, 90Y-radiolabeled P96.5 demonstrates comparable tumor targeting and percentages of tumor dose found in normal organs. To test the therapeutic potential of 90Y-radiolabeled P96.5, tumors and normal sites were implanted with miniature thermoluminescent dosimeters (TLD). Seven days following administration of 100 microCi 90Y-radiolabeled P96.5, average absorbed doses of 3770, 980, 353, and 274 cGy were observed in tumor, liver, contralateral control site, and total body, respectively. Shared cell surface antigens among neuroectodermally derived neoplasms provide a basis for exploration of human glioma radioimmunotherapy.
Collapse
Affiliation(s)
- J A Williams
- Division of Radiation Oncology, Johns Hopkins Oncology Center, Baltimore, MD 21205
| | | | | | | | | | | | | |
Collapse
|
4
|
Abstract
The present day use of systemically administered isotopes and conjugated isotopic combinations are reviewed. Administration of 131Iodine in thyroid cancer led to a 97% local control and 50% complete remission of pulmonary metastases. Specificity directed isotopic therapy (metabolic, hormonal, and antibody) is discussed and includes factors such as tumor physiology and isotopic linkage. The clinical results and new knowledge being gained in Hodgkin's disease, non-Hodgkin's, colorectal, hepatoma, intrahepatic biliary and gliomatous cancers are reviewed. The dose response relationship to tumor remission is demonstrated in Hodgkin's treated with 131I antiferritin (40% partial remission) and more recently 90Yttrium antiferritin (50% complete response). Varied routes of administration, the problem of anti-antibody and bone marrow transplantation are discussed. Finally, the challenge to radiobiologists, physicists, chemists, immunologists, nuclear radiologists, and radiation oncologists is emphasized by definition of the new laboratory and clinical approaches being developed in systemic radiation therapy.
Collapse
Affiliation(s)
- S E Order
- Johns Hopkins Oncology Center, Department of Radiation Oncology, Baltimore, MD 21205
| |
Collapse
|
5
|
Order SE. The theoretical implications and experimental and clinical results of radiolabeled antiferritin. Acta Oncol 1990; 29:689-94. [PMID: 2223137 DOI: 10.3109/02841869009092985] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Ferritin is produced in malignant and normal tissues. It acts both as an immunosuppressant and as an iron storage protein. As a tumor associated protein, it is related to virally induced tumors, and selective tumor targeting by radiolabeled antiferritin antibodies has led to its use in clinical trials. In patients with advanced Hodgkin's disease who have failed conventional therapy, 131I antiferritin produced partial remissions, while 90Y antiferritin led to complete remissions and a demonstrable dose-response relationship. Combining the variable low-dose radiation patterns produced by radiolabeled antibody therapy with chemotherapy in the treatment of hepatocellular cancer has led to enhanced tumor cytotoxicity and, in some cases, the conversion of non-resectable hepatoma to resectable. Further, the potential for clinical and laboratory investigation of radiolabeled antibody therapy is discussed in light of new findings.
Collapse
Affiliation(s)
- S E Order
- Department of Radiation Oncology, Johns Hopkins Hospital, Baltimore, Maryland
| |
Collapse
|
6
|
Macklis RM, Kaplan WD, Ferrara JL, Atcher RW, Hines JJ, Burakoff SJ, Coleman CN. Alpha particle radio-immunotherapy: animal models and clinical prospects. Int J Radiat Oncol Biol Phys 1989; 16:1377-87. [PMID: 2470706 DOI: 10.1016/0360-3016(89)90938-3] [Citation(s) in RCA: 33] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Short-lived isotopes that emit alpha particles have a number of physical characteristics which make them attractive candidates for radioimmunotherapy. Among these characteristics are high linear energy transfer and correspondingly high cytotoxicity; particle range limited to several cell diameters from the parent atom; low potential for repair of alpha-induced DNA damage; and low dependence on dose rate and oxygen enhancement effects. This report reviews the synthesis, testing and use in animal models of an alpha particle emitting radioimmunoconjugate constructed via the noncovalent chelation of Bismuth-212 to a monoclonal IgM antibody specific for the murine T cells/neuroectodermal surface antigen, Thy 1.2. These 212Bi-anti-Thy 1.2 immunoconjugates are capable of extraordinary cytotoxicity in vitro, requiring approximately three 212Bi-labeled conjugates per target cell to suppress 3H-thymidine incorporation to background levels. The antigen specificity afforded by the monoclonal antibody contributes a factor of approximately 40 to the radiotoxicity of the immunoconjugate. Animals inoculated with a Thy 1.2+ malignant ascites were cured of their tumor in an antigen-specific fashion by intraperitoneal doses of approximately 200 microCi per mouse. Alpha particle emitting radioimmunoconjugates show great potential for regional and intracavitary molecular radiotherapy.
Collapse
Affiliation(s)
- R M Macklis
- Department of Radiology, Dana Farber Cancer Institute, Boston, MA 02115
| | | | | | | | | | | | | |
Collapse
|
7
|
Affiliation(s)
- V Keegan-Rogers
- Department of Medicine, University of Connecticut Health Center, Farmington 06032
| | | |
Collapse
|
8
|
Abstract
The ability to convert a nonrectable lesion into a resectable one offers significant palliation and possible cure for patients with hepatoma. With increasing effectiveness of radiolabeled immunoglobulin and multimodality treatment, more patients are expected to become candidates for definitive resection after presenting with unresectable disease.
Collapse
|
9
|
|
10
|
|
11
|
Msirikale JS, Klein JL, Schroeder J, Order SE. Radiation enhancement of radiolabelled antibody deposition in tumors. Int J Radiat Oncol Biol Phys 1987; 13:1839-44. [PMID: 3679921 DOI: 10.1016/0360-3016(87)90349-x] [Citation(s) in RCA: 62] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Recent clinical observations led to the use of external radiation to increase tumor targeting by radiolabelled 131-I antiferritin. Examination of increased uptake of 131-I labelled antiferritin following external radiation was carried out in syngeneic implanted hepatomas (H4IIE, 3924A, 7800, and 7777). Exposure to 10 Gy increased the tumor: liver uptake ratio from 1.55 to 1.86 for H4IIE; from 1.56 to 2.0 for 7800; from 1.34 to 1.97 for 7777; and from 1.05 to 1.19 for 3924A. The pattern of uptake varied among the different tumor types, reflecting their inherent differences in vascularity, tumor permeability, antigen density and growth rate, all of which influence antibody targeting of the tumors. When tumor and liver were irradiated, the tumor showed increased differential uptake of labelled antibody compared to normal liver. 51-Cr labelled erythrocytes were used to study the relative vascularity and blood pooling in H4IIE hepatoma and normal tissue. External radiation to the tumor did not increase the uptake of 51-Cr labelled erythrocytes in any site. These studies provide an insight into the role of external radiation as a modality that increases radiolabelled antibody targeting in hepatoma.
Collapse
Affiliation(s)
- J S Msirikale
- Department of Radiation Oncology, Johns Hopkins Hospital, Baltimore, MD 21205
| | | | | | | |
Collapse
|
12
|
Brady LW, Woo DV, Heindel ND, Markoe AM, Koprowski H. Therapeutic and diagnostic uses of modified monoclonal antibodies. Int J Radiat Oncol Biol Phys 1987; 13:1535-44. [PMID: 3305445 DOI: 10.1016/0360-3016(87)90322-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
13
|
Wilson CB, Epenetos AA. Use of monoclonal antibodies for diagnosis and treatment of liver tumours. BAILLIERE'S CLINICAL GASTROENTEROLOGY 1987; 1:115-30. [PMID: 3034355 DOI: 10.1016/0950-3528(87)90036-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Antibody-guided diagnosis can provide information regarding malignant disease which is not obtainable by conventional techniques and in some instances this approach can help to achieve prolonged tumour-free survival. Nevertheless, there are many technology improvements that need to be made if this method is to be widely applied for routine diagnosis and therapy. Already, encouraging therapeutic responses have been reported using 131I-labelled polyclonal and monoclonal antibodies in the treatment of primary and metastatic liver tumours. It is essential, however, to improve the radiolabelling of monoclonal antibodies for therapeutic use. It would be more convenient and effective to use radioactive isotopes which are pure beta emitters, e.g. 90Y and 32P which would allow for outpatient therapy. It is essential to evaluate the use of multiple antibodies or antibodies that bind to multiple antigenic targets within tumours to improve dose rate and total dose amplification. Finally, encouraging clinical pilot studies should be followed up by documented randomized clinical trials in order to define properly the clinical place of monoclonal antibodies, in both the diagnosis and the therapy of malignant disease, including primary and metastatic liver tumours.
Collapse
|
14
|
Order SE, Klein JL, Leichner PK, Frincke J, Lollo C, Carlo DJ. 90Yttrium antiferritin--a new therapeutic radiolabeled antibody. Int J Radiat Oncol Biol Phys 1986; 12:277-81. [PMID: 3005201 DOI: 10.1016/0360-3016(86)90110-0] [Citation(s) in RCA: 86] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
A new radiolabel 90Yttrium has been chelated to antiferritin antibodies for the treatment of hepatocellular cancer. The isotope 90Yttrium has the advantage of no significant external radiation to other individuals, that is, outpatient therapy and potentially more therapeutic power with an increase from 0.3 Mev 131I beta radiation to 0.9 Mev 90Yttrium pure beta radiation. Six patients treated in the Phase I study have had modest hematologic toxicity and two have had partial remissions of their primary tumors. One of these patients has had complete remission of a pulmonary metastasis. The use of external radiation (900 rad) to the primary tumor in advance of radiolabeled antibody administration has increased antibody uptake and increased tumor dose rate and total dose. An extensive study of 90Yttrium antiferritin is planned.
Collapse
|
15
|
Mather SJ. Radioiodinated monoclonal antibodies: a critical review. INTERNATIONAL JOURNAL OF RADIATION APPLICATIONS AND INSTRUMENTATION. PART A, APPLIED RADIATION AND ISOTOPES 1986; 37:727-33. [PMID: 3021674 DOI: 10.1016/0883-2889(86)90267-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
16
|
Klein JL, Kopher KA, Rostock RA. Ferritin concentration and 131I-antiferritin tumor localization in an experimental hepatoma. Int J Radiat Oncol Biol Phys 1986; 12:137-40. [PMID: 3943985 DOI: 10.1016/0360-3016(86)90428-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Polyclonal 131I-labeled rabbit anti-rat ferritin was shown to specifically localize in the H4IIe rat hepatoma model. Tumor targeting was shown to be maximal in primary tumors or metastatic lesions less than 1 gram. Radiolabeled antiferritin tumor targeting decreased with increasing tumor size. In this study, ferritin levels were measured in H4IIe tumors grown both in vitro and in vivo. In vitro tumor cells synthesized and secreted ferritin into the medium as measured by radioimmunoassay, and confirmed by the incorporation of 14C-leucine into ferritin synthesis. The concentration of ferritin in the tumor cells as measured by radioimmunoassay remained relatively constant over this same time period. In vivo tumor ferritin levels in whole tumor extracts were highest in small tumors (less than 1 gram) and decreased as the tumors became larger. Serum ferritin levels of tumor-bearing animals paralleled the level in the tumors themselves. The elevated serum ferritin levels in animals with small tumors did not inhibit tumor targeting with radiolabeled antiferritin antibody. These findings are a foundation for understanding the selective tumor targeting of tumor associated proteins by radiolabeled antibodies, which includes factors such as tumor size, vascularity, antigen content, and circulating antigen.
Collapse
|
17
|
Order SE, Klein JL, Leichner PK, Ettinger DS, Kopher K, Finney K, Surdyke M, Leibel SA. Radiolabeled antibody in the treatment of primary and metastatic liver malignancies. Recent Results Cancer Res 1986; 100:307-14. [PMID: 3016844 DOI: 10.1007/978-3-642-82635-1_38] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
18
|
Klein JL, Ling MN, Leichner PK, Kopher KA, Rostock RA, Order SE. A model system that predicts effective half-life for radiolabeled antibody therapy. Int J Radiat Oncol Biol Phys 1985; 11:1489-94. [PMID: 3926734 DOI: 10.1016/0360-3016(85)90337-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Radiolabeled antibodies to tumor associated proteins localize in both experimental and clinical cancers. In the therapeutic applications of radiolabeled antibody, tumor effective half-life (composite of biological and physical half-lives), along with the concentration of isotope deposited and energies of the isotope used, determine the tumor dose. Antibodies directed against the same antigenic specificity but derived from different species have varied tumor and whole body effective half-lives and as a result, achieve different tumor doses. In vitro testing does not evaluate the in vivo differences in effective half-life that affect tumor dose. We have developed an animal model to evaluate the effective half-life and biodistribution of radiolabeled immunoglobulin (IgG) from diverse species. To determine the relevance of such a model, the effective half-lives and tissue distributions of the different immunoglobulins in the model were compared to those obtained from the clinical program using the same radiolabeled antibody preparations. In both the experimental model and in the clinical trials, radiolabeled immunospecific and normal IgG derived from monkey, rabbit, and porcine sources had the longest effective half-lives, goat and sheep had intermediate effective half-lives, and chicken and turkey had the shortest effective half-lives. Prescreening of bovine and baboon normal IgG predict long half-lives and similar organ distributions. These species have been immunized for clinical use. Bovine IgG has a long clinical half-life and has been added to our other successful antibodies. Baboon IgG is now ready for clinical testing. The value of this model system is that it appears to be an effective in vivo preclinical screen for tumor effective half-life of antibodies and IgG from diverse species, thus guiding potential clinical use.
Collapse
|
19
|
DeNardo GL, Raventos A, Hines HH, Scheibe PO, Macey DJ, Hays MT, DeNardo SJ. Requirements for a treatment planning system for radioimmunotherapy. Int J Radiat Oncol Biol Phys 1985; 11:335-48. [PMID: 3882643 DOI: 10.1016/0360-3016(85)90156-7] [Citation(s) in RCA: 48] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Cancer-seeking antibodies carrying radionuclides can, in theory, be very powerful agents for the radiotherapy of cancer. However, as with all radiotherapy, the undesired dose to critical normal organs is the limiting factor that determines success or failure. The distribution of radiation dose in cancer and noncancer tissue is highly dependent on choices the therapist can make: choices of the antigens to be targeted, choices of the antibodies or antibody fragments to be used, choices of radionuclides, of amounts, of timing, and other electives. New technologies, especially of monoclonal antibody production, make the options myriad. Optimization of this therapy depends on a foreknowledge of the radiation dose distributions to be expected. The necessary data can be acquired by established tracer techniques, in individual patients, for particular treatment selections. These tracer techniques can now be implemented by advanced equipment for quantitative, tomographic radionuclide imaging and strengthened by dynamic modeling of the physiological parameters which govern radionuclide distribution, and hence radiation dose distribution.
Collapse
|
20
|
Rostock RA, Kopher KA, Bauer TW, Klein JL. Factors that affect antiferritin localization in four rat hepatoma models. CANCER DRUG DELIVERY 1985; 2:139-45. [PMID: 3902194 DOI: 10.1089/cdd.1985.2.139] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
The effect of tumor size, vascularity, ferritin content and the amount of injected 131I-antiferritin on tumor localization was studied in four hepatoma models with varying growth rates, histology, vascularity, and ferritin content. Separate groups of 12 animals with the H-4-II-E, 7800, 7777, and 3924A rat hepatomas with less than 2 g or greater than 2 g tumors were injected with escalating doses of 131I-antiferritin or 131I nonspecific IgG (control). Tumor vascularity was measured by 51Cr-labeled erythrocyte injection, ferritin content of tumors by radioimmunoassay and immunoperoxidase staining, and the histological location of 131I-antiferritin by autoradiography. 131I-antiferritin specifically localized in the H-4-II-E and 7800 models and correlated with the tumor size, vascular content, and amount of injected antiferritin. No localization took place in the 7777 or 3924A tumors despite the presence of ferritin in these models. The only factor that correlated with localization in the models was vascularity. The vascularity of 3924A and 7777 tumors was significantly reduced in comparison to the H-4-II-E and 7800 tumors. The dependence of targeting on vascularity was demonstrated with autoradiography as well. These findings indicate the correlation of vascularity and tumor localization with 131I-antiferritin.
Collapse
|
21
|
Rostock RA, Kopher KA, Bauer TW, Klein JL. The effect of iron dextran on ferritin content and 131I-antiferritin localization in experimental hepatomas. CANCER DRUG DELIVERY 1985; 2:3-9. [PMID: 3902193 DOI: 10.1089/cdd.1985.2.3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Polyclonal 131I rabbit antirat ferritin localizes in certain hepatoma models. The effect of intraperitoneal iron dextran on tumor and sera ferritin content and tumor and normal tissue localization with 131I antiferritin was studied. Separate groups of 10-12 animals were injected with escalating doses of 131I-antiferritin IgG, or nonspecific IgG, one week after injection with iron dextran or normal saline. The results demonstrate that tumor, serum, and normal tissue ferritin content was increased after iron dextran administration but tumor localization increased after administration of 131I-antiferritin in the H4II-E and 7800 models. The 3924A and 7777 models showed no tumor localization with or without iron dextran but did show an increase in normal tissue localization after iron dextran. Immunoperoxidase staining of tissues with antiferritin revealed increased staining in the liver and spleen and only a slight increase in the tumors after iron dextran was administered. The results demonstrate that tumor localization is a complex phenomenon that depends on normal tissue, sera, and tumor-antigen distribution.
Collapse
|
22
|
Rostock RA, Klein JL, Leichner PK, Order SE. Distribution of and physiologic factors that affect 131I-antiferritin tumor localization in experimental hepatoma. Int J Radiat Oncol Biol Phys 1984; 10:1135-41. [PMID: 6746354 DOI: 10.1016/0360-3016(84)90188-3] [Citation(s) in RCA: 34] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Polyclonal 131I rabbit anti-rat ferritin localizes in the H-4-II-E hepatoma model. The effect of tumor size, vascularity, and ferritin content on tumor localization was examined. The extravascular and intravascular quantity and location of 131I non-specific IgG and 131I-antiferritin IgG in tumors were determined by gamma counter analysis of tissue samples and autoradiography. Separate groups of 8-10 tumor bearing rats with 0.6-1 g, 1-3 g, 4-8 g, 8-14 g, and greater than 14 g tumors were injected with 500 microCi (200 micrograms) of 131I non-specific IgG or 131I-antiferritin. Tumor targeting with antiferritin occurred maximally in primary or metastatic lesions less than 1 g in size. Decreased localization occurred with increasing tumor size and no localization took place in tumors greater than 8 g in size. This finding is independent of administered dose because increasing the amount of injected antiferritin from 2- to 10-fold did not increase the antiferritin/normal IgG targeting ratio in any group of tumors greater than 4 g. The quantity and physical characteristics of the tumor vasculature may in part explain selective tumor localization. Tumor vascularity per gram as measured by 51Cr labeled erythrocytes decreased as tumor size increased. Decreased localization was evident in the necrotic portions of large tumors. Autoradiography of tumor sections revealed that most of the 125I-IgG activity is deposited perivascularly with decreased deposition of antibody in necrotic areas of tumors and at increasing distance from the lumen of vessels. These findings have clinical importance since this non-homogeneous distribution of antibody could result in the delivery of low doses of radiation to large necrotic areas of tumors. These results help to demonstrate some of the complex physiologic factors that affect tumor localization and antibody distribution.
Collapse
|